Retrospective analyses of cisplatin-based doublet combination chemotherapy in patients with advanced gastric cancer
<p>Abstract</p> <p>Backgrounds</p> <p>Cisplatin-based chemotherapy, in combination with fluoropyrimidines or taxanes, have demonstrated efficacy against advanced gastric cancer (AGC). This retrospective study was performed with the data obtained from our cancer chemothe...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2010-10-01
|
| Series: | BMC Cancer |
| Online Access: | http://www.biomedcentral.com/1471-2407/10/583 |
| _version_ | 1818327326573723648 |
|---|---|
| author | Kim Hyeong Lee Hui-Young Lee Sang-Cheol Kwon Jung Hwang In Oh Sung Kang Jung Park Keon Park Se Lim Do Lim Ho Kang Won |
| author_facet | Kim Hyeong Lee Hui-Young Lee Sang-Cheol Kwon Jung Hwang In Oh Sung Kang Jung Park Keon Park Se Lim Do Lim Ho Kang Won |
| author_sort | Kim Hyeong |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Backgrounds</p> <p>Cisplatin-based chemotherapy, in combination with fluoropyrimidines or taxanes, have demonstrated efficacy against advanced gastric cancer (AGC). This retrospective study was performed with the data obtained from our cancer chemotherapy registry and eight another cancer centers.</p> <p>Methods</p> <p>In 2008, a total of 283 AGC patients were treated with cisplatin-based doublet chemotherapy in the first-line setting: capecitabine plus cisplatin (XP, n = 77), S-1 plus cisplatin (SP, n = 97), taxanes (docetaxel, paclitaxel) plus cisplatin (TP, n = 72), and 5-fluorouracil plus platinum (FP, n = 37). The primary endpoint of this study was overall survival (OS) and the secondary endpoints were safety, response rate and progression-free survival (PFS).</p> <p>Results</p> <p>The median age was 54 years with a range of 28-78 years and median delivered number of chemotherapy cycles were XP: 4, SP: 5, TP: 5 and FP: 5, respectively. Objective tumor responses (38%; 95% CI, 32-43%) were 40% for XP, 42% for SP, 36% for DP, and 24% for FP. The estimated median PFS was 4.5 months (95% CI, 3.6-5.4 months) and the median OS was 12.3 months (95% CI, 10.8-13.7 months). No statistically significant difference was found between each regimen used as first-line chemotherapy. At multivariate analysis, independent prognostic parameters for OS were prior gastrectomy, peritoneal dissemination, performance status and hemoglobin level</p> <p>Conclusion</p> <p>All of the cisplatin-based doublet chemotherapy regimens appear to be active as first-line chemotherapy for AGC. With better patient selection according to clinical parameters and molecular markers, clinical outcomes of AGC patients in first-line setting can be improved.</p> |
| first_indexed | 2024-12-13T12:14:30Z |
| format | Article |
| id | doaj.art-3a4651e048464021b423bdfd9c9a7eb6 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-12-13T12:14:30Z |
| publishDate | 2010-10-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-3a4651e048464021b423bdfd9c9a7eb62022-12-21T23:46:45ZengBMCBMC Cancer1471-24072010-10-0110158310.1186/1471-2407-10-583Retrospective analyses of cisplatin-based doublet combination chemotherapy in patients with advanced gastric cancerKim HyeongLee Hui-YoungLee Sang-CheolKwon JungHwang InOh SungKang JungPark KeonPark SeLim DoLim HoKang Won<p>Abstract</p> <p>Backgrounds</p> <p>Cisplatin-based chemotherapy, in combination with fluoropyrimidines or taxanes, have demonstrated efficacy against advanced gastric cancer (AGC). This retrospective study was performed with the data obtained from our cancer chemotherapy registry and eight another cancer centers.</p> <p>Methods</p> <p>In 2008, a total of 283 AGC patients were treated with cisplatin-based doublet chemotherapy in the first-line setting: capecitabine plus cisplatin (XP, n = 77), S-1 plus cisplatin (SP, n = 97), taxanes (docetaxel, paclitaxel) plus cisplatin (TP, n = 72), and 5-fluorouracil plus platinum (FP, n = 37). The primary endpoint of this study was overall survival (OS) and the secondary endpoints were safety, response rate and progression-free survival (PFS).</p> <p>Results</p> <p>The median age was 54 years with a range of 28-78 years and median delivered number of chemotherapy cycles were XP: 4, SP: 5, TP: 5 and FP: 5, respectively. Objective tumor responses (38%; 95% CI, 32-43%) were 40% for XP, 42% for SP, 36% for DP, and 24% for FP. The estimated median PFS was 4.5 months (95% CI, 3.6-5.4 months) and the median OS was 12.3 months (95% CI, 10.8-13.7 months). No statistically significant difference was found between each regimen used as first-line chemotherapy. At multivariate analysis, independent prognostic parameters for OS were prior gastrectomy, peritoneal dissemination, performance status and hemoglobin level</p> <p>Conclusion</p> <p>All of the cisplatin-based doublet chemotherapy regimens appear to be active as first-line chemotherapy for AGC. With better patient selection according to clinical parameters and molecular markers, clinical outcomes of AGC patients in first-line setting can be improved.</p>http://www.biomedcentral.com/1471-2407/10/583 |
| spellingShingle | Kim Hyeong Lee Hui-Young Lee Sang-Cheol Kwon Jung Hwang In Oh Sung Kang Jung Park Keon Park Se Lim Do Lim Ho Kang Won Retrospective analyses of cisplatin-based doublet combination chemotherapy in patients with advanced gastric cancer BMC Cancer |
| title | Retrospective analyses of cisplatin-based doublet combination chemotherapy in patients with advanced gastric cancer |
| title_full | Retrospective analyses of cisplatin-based doublet combination chemotherapy in patients with advanced gastric cancer |
| title_fullStr | Retrospective analyses of cisplatin-based doublet combination chemotherapy in patients with advanced gastric cancer |
| title_full_unstemmed | Retrospective analyses of cisplatin-based doublet combination chemotherapy in patients with advanced gastric cancer |
| title_short | Retrospective analyses of cisplatin-based doublet combination chemotherapy in patients with advanced gastric cancer |
| title_sort | retrospective analyses of cisplatin based doublet combination chemotherapy in patients with advanced gastric cancer |
| url | http://www.biomedcentral.com/1471-2407/10/583 |
| work_keys_str_mv | AT kimhyeong retrospectiveanalysesofcisplatinbaseddoubletcombinationchemotherapyinpatientswithadvancedgastriccancer AT leehuiyoung retrospectiveanalysesofcisplatinbaseddoubletcombinationchemotherapyinpatientswithadvancedgastriccancer AT leesangcheol retrospectiveanalysesofcisplatinbaseddoubletcombinationchemotherapyinpatientswithadvancedgastriccancer AT kwonjung retrospectiveanalysesofcisplatinbaseddoubletcombinationchemotherapyinpatientswithadvancedgastriccancer AT hwangin retrospectiveanalysesofcisplatinbaseddoubletcombinationchemotherapyinpatientswithadvancedgastriccancer AT ohsung retrospectiveanalysesofcisplatinbaseddoubletcombinationchemotherapyinpatientswithadvancedgastriccancer AT kangjung retrospectiveanalysesofcisplatinbaseddoubletcombinationchemotherapyinpatientswithadvancedgastriccancer AT parkkeon retrospectiveanalysesofcisplatinbaseddoubletcombinationchemotherapyinpatientswithadvancedgastriccancer AT parkse retrospectiveanalysesofcisplatinbaseddoubletcombinationchemotherapyinpatientswithadvancedgastriccancer AT limdo retrospectiveanalysesofcisplatinbaseddoubletcombinationchemotherapyinpatientswithadvancedgastriccancer AT limho retrospectiveanalysesofcisplatinbaseddoubletcombinationchemotherapyinpatientswithadvancedgastriccancer AT kangwon retrospectiveanalysesofcisplatinbaseddoubletcombinationchemotherapyinpatientswithadvancedgastriccancer |